<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vasculitis in children: Incidence and classification</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vasculitis in children: Incidence and classification</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vasculitis in children: Incidence and classification</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Cabral, MBBS, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimberly Morishita, MD, MHSc, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Klein-Gitelman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vasculitides are disorders defined by the presence of inflammation in a blood vessel wall (vasculitis). The inflammation may occur as a primary process or secondary to an underlying disease. Clinical symptoms vary widely depending upon the types and location of the vessels involved, the extent of inflammation, and subsequent vessel wall damage with associated hemodynamic changes.</p><p>The nomenclature and framework for classifying the primary vasculitides has been according to the size and type of the involved blood vessels, the clinical manifestations, and the pathologic changes found within the vessel walls [<a href="#rid1">1,2</a>] and, more recently, for subclassification, the prominence or paucity of immunoglobulins in the vessel walls, the serologic presence or absence of antineutrophil cytoplasmic antibodies (ANCA), and the presumed underlying disease pathogenesis [<a href="#rid3">3</a>].</p><p>The classification of the primary childhood vasculitides are reviewed here. The approach to the child with suspected vasculitis and an overview of the management of children with vasculitic disorders are presented separately. The classification and approach to vasculitides in adults are also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview"</a> and  <a class="medical medical_review" href="/z/d/html/6403.html" rel="external">"Vasculitis in children: Management overview"</a> and  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Vasculitis is rare in children, with a reported incidence ranging from 12 to 53 cases per 100,000 children under 17 years of age [<a href="#rid4">4-6</a>], although even the upper end of this range is probably still an underestimate since these data were based upon voluntary surveys of clinicians serving limited segments of the population. Worldwide, immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) is the most common vasculitis, followed by Kawasaki disease. In Japan and other parts of Asia, however, Kawasaki disease is more common. Other rarer vasculitides in children include Takayasu arteritis (TAK; which occurs more frequently in children from the Far East and Africa [<a href="#rid7">7,8</a>]), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), primary angiitis of the central nervous system (PACNS), and polyarteritis nodosa (PAN) [<a href="#rid9">9</a>]. Eosinophilic GPA (formerly Churg-Strauss syndrome) is extremely rare in children, and temporal arteritis is not seen in pediatric patients [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/6416.html" rel="external">"Kawasaki disease: Epidemiology and etiology", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLASSIFICATION VERSUS DIAGNOSIS</span><span class="headingEndMark"> — </span>Classification criteria were developed in order to facilitate and improve research efforts by defining consistent and homogeneous patient populations for clinical protocols and outcome studies. Classification criteria were <strong>not</strong> developed to diagnose disease in individual persons and have not been validated for clinical diagnosis [<a href="#rid3">3</a>]. In particular, failure to meet the classification criteria does not necessarily preclude a specific diagnosis.</p><p>Even though the diagnostic accuracy of classification criteria for specific vasculitides is low [<a href="#rid10">10</a>], the rarity of childhood vasculitides means that individual clinicians with limited or no previous exposure to particular conditions may use classification criteria to assist in the diagnosis of individual patients [<a href="#rid9">9</a>]. The gold standard for diagnosing childhood vasculitis is with either histopathology from tissue biopsy samples or by characteristic lesions detected by imaging studies. However, diagnosis is more often based upon syndrome recognition in certain vasculitides such as Kawasaki disease, immunoglobulin A vasculitis (IgAV), and granulomatosis with polyangiitis (GPA).</p><p class="headingAnchor" id="H4"><span class="h1">CLASSIFICATION SYSTEMS</span><span class="headingEndMark"> — </span>The most widely used classification system has been the American College of Rheumatology (ACR) 1990 criteria derived from adult patient data [<a href="#rid1">1</a>], which was endorsed in 1994 by the Chapel Hill Consensus Conference (CHCC) [<a href="#rid2">2</a>]. With increasing knowledge since then, limitations of the ACR criteria for use in adult populations have been elucidated [<a href="#rid11">11</a>]. In addition, these criteria have performed poorly in pediatric populations [<a href="#rid1">1,9,12,13</a>], and they did not include immunoglobulin A vasculitis (IgAV) and Kawasaki disease.</p><p>A consensus-based framework for classifying pediatric vasculitis was proposed by the European Alliance of Associations for Rheumatology (then known as the European League Against Rheumatism)/Paediatric Rheumatology European Society (EULAR/PRES) in 2005 [<a href="#rid14">14</a>] and revised by EULAR/Paediatric Rheumatology International Trials Organisation (PRINTO)/PRES in 2008  (<a class="graphic graphic_table graphicRef115753" href="/z/d/graphic/115753.html" rel="external">table 1</a>). The framework also included specific pediatric classification criteria for IgAV, polyarteritis nodosum (PAN), granulomatosis with polyangiitis (GPA), and Takayasu arteritis (TAK) [<a href="#rid15">15</a>]. Because these criteria were adapted, in part, from the adult ACR criteria, they carried forward some of its limitations; however, they are the preferred and most commonly used criteria for children because they were based upon pediatric data.</p><p>Similar to the ACR criteria, the framework for the EULAR/PRINTO/PRES classification scheme is primarily based upon the size of the predominantly involved blood vessel, and small-vessel vasculitis (SVV) is subclassified into granulomatous and nongranulomatous types. Secondary vasculitis and types of vasculitis that are not easily categorized according to predominant vessel size are classified in the "other vasculitides" category.</p><p>A second Chapel Hill Consensus Conference held in 2012 (CHCC 2012) provides the most up-to-date nomenclature and broad framework for vasculitis classification along with specific disease definitions  (<a class="graphic graphic_table graphicRef115752" href="/z/d/graphic/115752.html" rel="external">table 2</a>) [<a href="#rid2">2,3</a>]. Included in CHCC 2012 are additional categories of variable-vessel vasculitis and single-organ vasculitis. Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) and immune complex vasculitis are subcategories of SVV that reflect more recent knowledge of underlying pathogenic mechanisms [<a href="#rid16">16</a>] rather than the previous granulomatous and nongranulomatous subcategories. Monogenic vasculitis was not included in CHCC 2012, because knowledge of this primary etiology emerged subsequently. The CHCC does not provide disease-specific classification or diagnostic criteria, but, in the absence of such for specific diseases such as microscopic polyangiitis (MPA), the provided descriptions are often used to help define diseases. (See  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a> and <a class="local">'Monogenic vasculitis'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">CLASSIFICATION CRITERIA</span></p><p class="headingAnchor" id="H3133737902"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Validated pediatric-specific classification criteria from 2008 (European Alliance of Associations for Rheumatology/Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology European Society [EULAR/PRINTO/PRES] criteria) are available for the most common pediatric primary vasculitides, namely immunoglobulin A vasculitis (IgAV), Takayasu arteritis (TAK), polyarteritis nodosa (PAN), and granulomatosis with polyangiitis (GPA) [<a href="#rid15">15</a>]. However, pediatric-specific criteria were not developed for some of the less common disorders.</p><p>Concurrently with the 2012 Chapel Hill Consensus Conference (CHCC 2012), an initiative called "Diagnostic and Classification Criteria in Vasculitis Study" (DCVAS) was established to collect data on adults with vasculitis and to use this to develop improved adult classification criteria. This has resulted in the endorsement and publication in 2022 of revised American College of Rheumatology (ACR)/EULAR criteria for the classification of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), which includes GPA [<a href="#rid17">17</a>], microscopic polyangiitis (MPA) [<a href="#rid18">18</a>], and eosinophilic granulomatosis with polyangiitis (EGPA) [<a href="#rid19">19</a>]. These criteria provide the first ever categorical criteria for classifying MPA, although the utility of these criteria in the pediatric population has yet to be evaluated. The adult classification criteria are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults", section on 'Classification criteria'</a>.)</p><p class="headingAnchor" id="H685648095"><span class="h2">Major primary vasculitides</span></p><p class="headingAnchor" id="H6"><span class="h3">IgA vasculitis (Henoch-Schönlein purpura)</span><span class="headingEndMark"> — </span>IgAV (HSP), the most common childhood vasculitis, is an immune-mediated vasculitis associated with IgA deposition.</p><p>The EULAR/PRINTO/PRES criteria for IgAV (HSP) include a mandatory finding of purpura (commonly palpable and in crops)  (<a class="graphic graphic_picture graphicRef72094" href="/z/d/graphic/72094.html" rel="external">picture 1</a>) or petechiae (without thrombocytopenia) with lower limb predominance and one or more of the following [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Arthritis or arthralgia</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytoclastic vasculitis or proliferative glomerulonephritis with predominant IgA deposition</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney involvement (hematuria, red blood cell casts, or proteinuria)</p><p></p><p>A biopsy demonstrating IgA deposits is required in the case of purpura with an atypical distribution. (See  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Kawasaki disease</span><span class="headingEndMark"> — </span>Kawasaki disease is an acute, self-limited vasculitis that occurs predominately in infants and young children [<a href="#rid20">20</a>]. This disorder mainly affects medium-sized arteries.</p><p>The EULAR/PRINTO/PRES classification criteria for Kawasaki disease are not validated; however, they are almost identical to the American Heart Association (AHA) diagnostic criteria, which are the most widely used criteria for the diagnosis of this disorder. (See  <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">"Kawasaki disease: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p>The criteria for Kawasaki disease include a mandatory finding of fever for five or more days and at least four of the five following features [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral bulbar conjunctival injection  (<a class="graphic graphic_picture graphicRef78898" href="/z/d/graphic/78898.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral mucous membrane changes, including injected or fissured lips  (<a class="graphic graphic_picture graphicRef59319" href="/z/d/graphic/59319.html" rel="external">picture 3</a>), injected pharynx, or strawberry tongue  (<a class="graphic graphic_picture graphicRef68321" href="/z/d/graphic/68321.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perineal or peripheral extremity changes, including erythema of palms or soles, edema of hands or feet (acute phase)  (<a class="graphic graphic_picture graphicRef72040" href="/z/d/graphic/72040.html" rel="external">picture 5</a>), and periungual or perineal desquamation (convalescent phase)  (<a class="graphic graphic_picture graphicRef53452" href="/z/d/graphic/53452.html" rel="external">picture 6</a>). Inclusion of perineal desquamation is a modification added by the EULAR/PRES classification to the AHA criteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polymorphous exanthema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical lymphadenopathy (at least one lymph node &gt;1.5 cm in diameter).</p><p></p><p>Patients with fever and fewer than four of the above criteria can also be diagnosed with Kawasaki disease if coronary artery abnormalities are detected either by two-dimensional echocardiography or coronary angiography.</p><p>In some cases, children who do not fulfill clinical criteria are diagnosed with incomplete or atypical Kawasaki disease. Alternatively, some patients who fulfill the criteria of Kawasaki disease may have other conditions, as is inevitable in any system based upon clinical manifestations. (See  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease"</a> and  <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">"Kawasaki disease: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Polyarteritis nodosa</span><span class="headingEndMark"> — </span>PAN (also called macroscopic polyarteritis or classic PAN) is a systemic necrotizing vasculitis with aneurysm formation affecting small- and/or medium-sized arteries. It typically presents with systemic symptoms (eg, fever, malaise, and weight loss) and signs of multisystem involvement. Recessive loss-of-function pathogenic variants of the cat eye syndrome chromosome region, candidate 1 (<em>CECR1</em>) gene encoding the growth factor adenosine deaminase 2 (ADA2) can cause a PAN-like disease [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and <a class="local">'Monogenic vasculitis'</a> below.)</p><p>The EULAR/PRINTO/PRES classification criteria for childhood PAN include a mandatory finding of abnormalities in a small- or medium-sized artery, either necrotizing vasculitis on biopsy  (<a class="graphic graphic_picture graphicRef74893" href="/z/d/graphic/74893.html" rel="external">picture 7</a>)<strong> or </strong>aneurysms, stenoses, or occlusions not due to fibromuscular dysplasia by angiography and at least one of the following five systemic features [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin involvement (livedo reticularis, tender subcutaneous nodules, superficial or deep skin infarctions)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myalgia or muscle tenderness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension (see  <a class="medical medical_review" href="/z/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy (sensory peripheral neuropathy or motor mononeuritis multiplex)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney involvement (proteinuria, hematuria, or red blood cell casts, or glomerular filtration rate of less than 50 percent the normal value for age)</p><p></p><p class="headingAnchor" id="H10"><span class="h4">Cutaneous polyarteritis nodosa</span><span class="headingEndMark"> — </span>The term "cutaneous polyarteritis nodosa" has frequently been used to describe patients that have a more limited disease presentation. EULAR/PRES in 2005 endorsed a description of cutaneous PAN as a distinct entity from systemic childhood PAN that involved the skin but with no other systemic involvement (except for myalgia, arthralgia, and nonerosive arthritis) [<a href="#rid14">14,22-25</a>]. There are no formal classification criteria for cutaneous PAN, and, in fact, many children with limited disease as described would fulfill classification criteria for childhood systemic PAN. In the absence of any specific criteria for cutaneous PAN, we consider cutaneous disease as part of the spectrum of childhood PAN.</p><p>Limited cutaneous disease was frequently associated with a preceding streptococcal infection [<a href="#rid22">22</a>]. However, such patients should no longer be diagnosed as PAN; the proper diagnostic term is "vasculitis associated with probable etiology." These changes in nomenclature of cutaneous vasculitis along with disease descriptions were described in a 2018 dermatologic addendum to the CHCC 2012 classification system [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Takayasu arteritis</span><span class="headingEndMark"> — </span>TAK is a chronic, inflammatory, large-vessel vasculitis of unknown cause that primarily affects the aorta and its major branches  (<a class="graphic graphic_diagnosticimage graphicRef64547" href="/z/d/graphic/64547.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef62264" href="/z/d/graphic/62264.html" rel="external">image 2</a>) [<a href="#rid27">27</a>]. Ongoing granulomatous inflammation leads to stenosis, thrombus, and aneurysm formation causing altered blood flow to major organs. (See  <a class="medical medical_review" href="/z/d/html/8238.html" rel="external">"Clinical features and diagnosis of Takayasu arteritis"</a>.)</p><p>The EULAR/PRINTO/PRES criteria for TAK in children require a mandatory finding of angiographic abnormalities of the aorta or its main branches and pulmonary arteries (aneurysm/dilatation, narrowing, occlusion, or arterial wall thickening not due to fibromuscular dysplasia) and at least one of the following five features [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulse deficit (lost/decreased/unequal peripheral artery pulse[s]) and/or claudication induced by activity</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic blood pressure difference &gt;10 mmHg between any limbs</p><p class="bulletIndent1"><span class="glyph">●</span>Bruits or thrills over the aorta and/or its major branches</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated acute-phase reactants</p><p></p><p>Angiographic confirmation may be performed by conventional radiography, computed tomography (CT), or magnetic resonance imaging (MRI).</p><p class="headingAnchor" id="H12"><span class="h3">Granulomatosis with polyangiitis</span><span class="headingEndMark"> — </span>GPA is a systemic vasculitis with granulomatous inflammation of small- and medium-sized arteries that typically affect the upper and lower respiratory tract and the kidneys [<a href="#rid28">28</a>]. It is usually associated with the presence of cytoplasmic antineutrophil cytoplasmic antibodies (cANCAs), generally with specificity for proteinase 3 (PR3)  (<a class="graphic graphic_picture graphicRef66748" href="/z/d/graphic/66748.html" rel="external">picture 8</a>). GPA is a rare disease in childhood, with an estimated annual incidence of less than one per one million children [<a href="#rid29">29-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a> and <a class="local">'Other childhood primary vasculitides'</a> below.)</p><p>The EULAR/PRINTO/PRES classification criteria for GPA require three of the following six features [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney involvement (hematuria, proteinuria, or red blood cell casts, or necrotizing pauci-immune glomerulonephritis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upper airway involvement (chronic/recurrent purulent or bloody nasal discharge or crusting, recurrent epistaxis, nasal septum perforation/saddle nose deformity, or chronic/recurrent sinus inflammation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laryngotracheobronchial stenosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary involvement (chest radiograph, CT showing nodules, cavities, or fixed infiltrates)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ANCA positivity (myeloperoxidase [MPO]/pANCA or PR3/cANCA staining)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area on biopsy</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Other childhood primary vasculitides</span><span class="headingEndMark"> — </span>Although the following primary vasculitides were included in the EULAR/PRES classification schema, classification criteria were not developed for these disorders [<a href="#rid14">14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Microscopic polyangiitis (MPA)</p><p class="bulletIndent1"><span class="glyph">●</span>Eosinophilic GPA (EGPA; Churg-Strauss syndrome)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity vasculitis</p><p class="bulletIndent1"><span class="glyph">●</span>Behçet syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Primary angiitis of the central nervous system (PACNS)</p><p></p><p>GPA, MPA, and EGPA are collectively classified as the ANCA-associated vasculitides (AAV) in CHCC 2012. They also each involve predominantly small arteries. The most important reason for this collective classification is that the definitions and classification criteria for each of these disorders are not mutually exclusive. Thus, an individual patient could be classified as having two of these diseases or even PAN. To overcome this conundrum, algorithms have been developed for adults [<a href="#rid32">32</a>] and adapted for use in children [<a href="#rid33">33,34</a>] whereby disease definitions and criteria are applied to the individual patient in a stepwise approach. The definition and criteria for eosinophilic GPA are the most specific; therefore, they are applied first. If the patient does not fulfill criteria, then the remaining elements of different criteria are sequentially applied until the patient is classified.</p><p class="headingAnchor" id="H4063968331"><span class="h3">Microscopic polyangiitis</span><span class="headingEndMark"> — </span>MPA is a vasculitis that predominantly affects small vessels without granuloma formation. Compared with PAN (macroscopic polyarteritis), MPA has extensive glomerular involvement, usually manifesting as focal segmental glomerulonephritis. This disorder also often involves the pulmonary capillaries, resulting in pulmonary hemorrhage.</p><p>MPA is thought by some investigators to represent part of a clinical spectrum that includes GPA. The two disorders have similar nonpulmonary histologic abnormalities and are associated with the presence of ANCAs. However, most patients with microscopic polyangiitis have anti-MPO ANCA present in a perinuclear pattern, in contrast to patients with GPA who demonstrate a primarily PR3 ANCA staining with cytoplasmic distribution  (<a class="graphic graphic_picture graphicRef66748" href="/z/d/graphic/66748.html" rel="external">picture 8</a> and <a class="graphic graphic_picture graphicRef78968" href="/z/d/graphic/78968.html" rel="external">picture 9</a>). (See  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p>The 2022 ACR/EULAR criteria for MPA were developed together with GPA and EGPA to be mutually exclusive [<a href="#rid17">17-19</a>]. However, if ACR/EULAR criteria for MPA is applied to an individual patient concurrently with the EULAR/PRINTO/PRES criteria for GPA, the patient may fulfill criteria for both GPA and MPA. The utility of the ACR/EULAR criteria for MPA in pediatric patients remains to be determined.</p><p class="headingAnchor" id="H14"><span class="h3">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)</span><span class="headingEndMark"> — </span>Eosinophilic GPA (formerly called Churg-Strauss syndrome and also called allergic granulomatosis and angiitis) is a predominantly small-vessel vasculitis (SSV) that is accompanied by asthma and eosinophilia. ANCA directed against both PR3 and MPO may be seen [<a href="#rid7">7,35</a>]. It is generally considered an adult disease and is exceedingly rare in children. Published childhood cases are limited to single case reports or series that have been collectively reviewed [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p>Classification of this disorder has been based upon criteria developed by the ACR in 1990 [<a href="#rid1">1</a>], and criteria were proposed as part of the 2022 ACR/EULAR criteria [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults", section on 'Classification criteria'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Hypersensitivity vasculitis</span><span class="headingEndMark"> — </span>The term "hypersensitivity vasculitis" has been used to include several forms of vasculitis of small blood vessels, including IgAV, mixed cryoglobulinemia, allergic vasculitis, leukocytoclastic vasculitis, and serum sickness. However, the term is used most appropriately to refer to the vasculitis that occurs as a part of a hypersensitivity reaction to a known or suspected antigen. (See  <a class="medical medical_review" href="/z/d/html/6404.html" rel="external">"Hypersensitivity vasculitis in children"</a>.)</p><p>The major feature of this disorder is vasculitis of the skin with palpable petechiae or purpura. Biopsy of the lesions demonstrates inflammation of the small blood vessels, usually with a predominant infiltration of leukocytes, hence its inclusion within the histopathologic classification framework of leukocytoclastic vasculitis.</p><p>Classification of this disorder is based upon criteria developed by the ACR and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults", section on 'Classification criteria'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Behçet syndrome</span><span class="headingEndMark"> — </span>Behçet syndrome is a multisystem inflammatory disorder characterized by recurrent oral ulcers, genital ulcers, and ocular inflammation, which may involve the joints, skin, central nervous system (CNS), and gastrointestinal tract. It is a systemic vasculitis that can affect both the arteries and veins of almost any organ. There is no universal agreement about the definition of this syndrome. A number of classification systems have been proposed, which are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome"</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Primary angiitis of the central nervous system</span><span class="headingEndMark"> — </span>PACNS, also called isolated CNS vasculitis, is an inflammatory vasculitis that solely affects the CNS vessels in the absence of an overt systemic inflammatory process [<a href="#rid37">37</a>]. Identifiable systemic conditions, such as an infectious process, a systemic vasculitis, collagen vascular diseases, toxin/drug exposure, or malignancy, must be ruled out. (See  <a class="medical medical_review" href="/z/d/html/16367.html" rel="external">"Childhood primary angiitis of the central nervous system: Angiography-positive subtype"</a>.)</p><p>Specific criteria for a diagnosis of PACNS have not yet been established for children; however, the proposed adult-based Calabrese criteria are frequently used [<a href="#rid38">38</a>], though several limitations have subsequently been identified [<a href="#rid39">39</a>]. A review based upon 62 children with PACNS vasculitis found that headache (80 percent) and focal neurologic deficits (78 percent) were the most common presenting complaints, followed by hemiparesis in 62 percent [<a href="#rid40">40</a>]. There are no reliable laboratory findings in children with primary CNS vasculitis, and diagnosis relies on a combination of clinical findings and tests including cerebrospinal fluid analysis, MRI of the brain, and/or angiography [<a href="#rid41">41</a>]. Small-vessel involvement may be missed on conventional angiography, and a brain biopsy may be required for diagnosis [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Secondary vasculitis</span><span class="headingEndMark"> — </span>Vasculitis in children may be secondary to a wide range of disorders. These conditions seem to represent a heightened susceptibility to vascular inflammation because most people exposed to these triggers do not develop vasculitis [<a href="#rid7">7</a>]. Causes of secondary vasculitis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Infectious causes including parvovirus B19, hepatitis B and C, human immunodeficiency virus (HIV), varicella, Rickettsia, bacteria, fungi, and mycobacteria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications including some antibiotics, tumor necrosis factor (TNF) inhibitors, and antithyroid agents</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic diseases including systemic lupus erythematosus (SLE), juvenile dermatomyositis, juvenile idiopathic arthritis, sarcoidosis, inflammatory bowel disease, and malignancy</p><p></p><p>Under the CHCC 2012 nomenclature system, secondary vasculitis is captured under "vasculitis associated with systemic disease" and "vasculitis associated with probable etiology"  (<a class="graphic graphic_table graphicRef115752" href="/z/d/graphic/115752.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H126060190"><span class="h2">Monogenic vasculitis</span><span class="headingEndMark"> — </span>Monogenic conditions that can present with vasculitis of the skin and other organs have been identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Loss-of-function pathogenic variants in the gene encoding adenosine deaminase 2 (ADA2) can cause a disease that mimics PAN [<a href="#rid21">21,43</a>]. (See <a class="local">'Polyarteritis nodosa'</a> above and  <a class="medical medical_review" href="/z/d/html/3907.html" rel="external">"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenic variants in <em>TMEM173</em>, the gene encoding the stimulator of interferon genes (STING), causes a disease called STING-associated vasculopathy with onset in infancy (SAVI) [<a href="#rid44">44</a>]. SAVI is characterized by early-onset systemic inflammation, cutaneous vasculopathy, and pulmonary inflammation [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)", section on 'STING-associated vasculopathy with onset in infancy (SAVI)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) can present with neutrophilic dermatosis that can mimic cutaneous vasculitis [<a href="#rid45">45</a>]. CANDLE has been linked to pathogenic variants in the proteasome pathway [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)", section on 'CANDLE'</a>.)</p><p></p><p>These disease entities have not yet been considered for incorporation into any formal classification schemes for either primary or secondary systemic vasculitis.</p><p class="headingAnchor" id="H2999290436"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Vasculitides are disorders defined by the presence of inflammation in a blood vessel wall (vasculitis) due to a primary process or secondary to an underlying disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Vasculitis is rare in children, with reported annual incidences that range from 12 to 53 per 100,000 children under 17 years of age. (See <a class="local">'Incidence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification versus diagnosis</strong> – Classification systems have been developed to standardize the definitions of specific vasculitides to facilitate research efforts of these disorders. They were not developed to diagnose disease and have not been validated for clinical diagnosis. (See <a class="local">'Classification versus diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification systems</strong> – Classification systems and classification criteria for vasculitis in both children and adults are evolving as mechanistic pathways (eg, antineutrophil cytoplasmic antibody [ANCA] associated versus immune complex small-vessel vasculitis [SVV]) and genetic underpinnings (monogenic vasculitis) unfold. (See <a class="local">'Classification systems'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification criteria</strong> – There are validated pediatric-specific classification criteria (European Alliance of Associations for Rheumatology [previously known as the European League Against Rheumatism]/Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology European Society [EULAR/PRINTO/PRES] criteria) for some of the pediatric primary vasculitides including immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), childhood polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), and Takayasu arteritis (TAK). (See <a class="local">'Classification criteria'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990; 33:1065.</a></li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.</a></li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a class="nounderline abstract_t">Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360:1197.</a></li><li><a class="nounderline abstract_t">Dolezalová P, Telekesová P, Nemcová D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol 2004; 31:2295.</a></li><li><a class="nounderline abstract_t">Ozen S, Bakkaloglu A, Dusunsel R, et al. Childhood vasculitides in Turkey: a nationwide survey. Clin Rheumatol 2007; 26:196.</a></li><li><a class="nounderline abstract_t">Dedeoglu F, Sundel RP. Vasculitis in children. Rheum Dis Clin North Am 2007; 33:555.</a></li><li><a class="nounderline abstract_t">Schnabel A, Hedrich CM. Childhood Vasculitis. Front Pediatr 2018; 6:421.</a></li><li><a class="nounderline abstract_t">Wilkinson NM, Page J, Uribe AG, et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 2007; 34:224.</a></li><li><a class="nounderline abstract_t">Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998; 129:345.</a></li><li><a class="nounderline abstract_t">Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis--is it time to reclassify? Rheumatology (Oxford) 2011; 50:643.</a></li><li><a class="nounderline abstract_t">Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996; 23:1981.</a></li><li><a class="nounderline abstract_t">Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol 1996; 23:1968.</a></li><li><a class="nounderline abstract_t">Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936.</a></li><li><a class="nounderline abstract_t">Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69:798.</a></li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.</a></li><li><a class="nounderline abstract_t">Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis Rheumatol 2022; 74:393.</a></li><li><a class="nounderline abstract_t">Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis Rheumatol 2022; 74:400.</a></li><li><a class="nounderline abstract_t">Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol 2022; 74:386.</a></li><li><a class="nounderline abstract_t">Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 1967; 16:178.</a></li><li><a class="nounderline abstract_t">Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014; 370:921.</a></li><li><a class="nounderline abstract_t">David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child 1993; 69:685.</a></li><li><a class="nounderline abstract_t">Fink CW. The role of the streptococcus in poststreptococcal reactive arthritis and childhood polyarteritis nodosa. J Rheumatol Suppl 1991; 29:14.</a></li><li><a class="nounderline abstract_t">Till SH, Amos RS. Long-term follow-up of juvenile-onset cutaneous polyarteritis nodosa associated with streptococcal infection. Br J Rheumatol 1997; 36:909.</a></li><li><a class="nounderline abstract_t">Sheth AP, Olson JC, Esterly NB. Cutaneous polyarteritis nodosa of childhood. J Am Acad Dermatol 1994; 31:561.</a></li><li><a class="nounderline abstract_t">Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018; 70:171.</a></li><li><a class="nounderline abstract_t">Brunner J, Feldman BM, Tyrrell PN, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford) 2010; 49:1806.</a></li><li><a class="nounderline abstract_t">Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum 2009; 60:3413.</a></li><li><a class="nounderline abstract_t">Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39:87.</a></li><li><a class="nounderline abstract_t">Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 2000; 43:2481.</a></li><li><a class="nounderline abstract_t">Stegmayr BG, Gothefors L, Malmer B, et al. Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol 2000; 14:208.</a></li><li><a class="nounderline abstract_t">Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66:222.</a></li><li><a class="nounderline abstract_t">Uribe AG, Huber AM, Kim S, et al. Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis. J Rheumatol 2012; 39:1687.</a></li><li><a class="nounderline abstract_t">Cabral DA, Canter DL, Muscal E, et al. Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis Rheumatol 2016; 68:2514.</a></li><li><a class="nounderline abstract_t">Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.</a></li><li><a class="nounderline abstract_t">Gendelman S, Zeft A, Spalding SJ. Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort. J Rheumatol 2013; 40:929.</a></li><li><a class="nounderline abstract_t">Smitka M, Bruck N, Engellandt K, et al. Clinical Perspective on Primary Angiitis of the Central Nervous System in Childhood (cPACNS). Front Pediatr 2020; 8:281.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 1988; 67:20.</a></li><li><a class="nounderline abstract_t">Twilt M, Benseler SM. Central nervous system vasculitis in adults and children. Handb Clin Neurol 2016; 133:283.</a></li><li><a class="nounderline abstract_t">Benseler S, Schneider R. Central nervous system vasculitis in children. Curr Opin Rheumatol 2004; 16:43.</a></li><li><a class="nounderline abstract_t">Eleftheriou D, Cox T, Saunders D, et al. Investigation of childhood central nervous system vasculitis: magnetic resonance angiography versus catheter cerebral angiography. Dev Med Child Neurol 2010; 52:863.</a></li><li><a class="nounderline abstract_t">Benseler SM, deVeber G, Hawkins C, et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum 2005; 52:2159.</a></li><li><a class="nounderline abstract_t">Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370:911.</a></li><li><a class="nounderline abstract_t">Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371:507.</a></li><li><a class="nounderline abstract_t">Torrelo A, Patel S, Colmenero I, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol 2010; 62:489.</a></li><li><a class="nounderline abstract_t">Liu Y, Ramot Y, Torrelo A, et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012; 64:895.</a></li><li><a class="nounderline abstract_t">Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 2015; 125:4196.</a></li></ol></div><div id="topicVersionRevision">Topic 6401 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2390119" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129773" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nomenclature of systemic vasculitides. Proposal of an international consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045170" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401245" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15517648" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586044" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Childhood vasculitides in Turkey: a nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17936177" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Vasculitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30687686" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Childhood Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17117484" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9735061" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647295" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systemic vasculitis--is it time to reclassify?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923379" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923377" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322081" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413568" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366584" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Small-vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35106964" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35106973" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35106968" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6062087" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552285" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904442" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Polyarteritis nodosa associated with streptococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1678431" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The role of the streptococcus in poststreptococcal reactive arthritis and childhood polyarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291862" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term follow-up of juvenile-onset cutaneous polyarteritis nodosa associated with streptococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7916355" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cutaneous polyarteritis nodosa of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29136340" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20562196" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Takayasu arteritis in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877069" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546743" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083271" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Epidemiology of Wegener's granulomatosis in northern Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752759" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Wegener granulomatosis in children and young adults. A case study of ten patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901958" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22589257" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111558" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263885" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23637321" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32719754" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical Perspective on Primary Angiitis of the Central Nervous System in Childhood (cPACNS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275856" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27112683" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Central nervous system vasculitis in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673388" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Central nervous system vasculitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132140" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Investigation of childhood central nervous system vasculitis: magnetic resonance angiography versus catheter cerebral angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15986347" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552284" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Early-onset stroke and vasculopathy associated with mutations in ADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029335" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Activated STING in a vascular and pulmonary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159315" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21953331" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mutations in proteasome subunitβtype 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26524591" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
